A carregar...

Development of Intranasal Levothyroxine Powder Delivery for Hypothyroidism

Background: Hypothyroidism affects 3-5% of the general population with oral levothyroxine (LT4) being the predominant replacement therapy. However, significant proportion of hypothyroid patients are unable to absorb oral replacement leading to therapeutic failure and may require injectable thyroxine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Imran, Syed Ali, Esomchukwu, Obinna, Agu, Remigius
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089816/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!